Skip to main content

Advertisement

SpringerLink
Log in

Ablative Treatment of Breast Cancer; Are We There Yet?

  • Local-Regional Evaluation and Therapy (DM Euhus, Section Editor)
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

A Correction to this article was published on 15 June 2019

This article has been updated

Abstract

Purpose of Review

Breast cancer treatment has evolved through continuous integration of technological advances and changes in our understanding of tumor biology. Radical mastectomy was the best operation for the technology and beliefs of its time. Advances in technology, the acknowledgement that care is best delivered through a multi-modal approach, and continued investigation have resulted in less disfiguring procedures. Ablative therapy for the treatment of breast cancer is the natural continuation of this trend.

Recent Findings

Data from breast cancer ablation trials utilizing various energy forms have been favorable and have led to the development of ongoing multi-center treat and observe studies.

Summary

This paper examines the current status of cryoablation, laser ablation, and focused ultrasound ablation for the treatment of breast cancers. The advantages and shortcomings of each technique are considered and the challenges to be met in order for ablative therapy to become a mainstream clinical treatment of breast cancer are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

Change history

  • 18 June 2019

    The original version of this article unfortunately contained a mistake in the article title. The captured title was “Local-Regional Evaluation and Therapy (D Euhus, Section Editor)” instead of “Ablative Treatment of Breast Cancer; Are We There Yet?”

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Sabel MS, Nehs MA, Su GK, Lowler KP, Ferrara JLM, Chang AE. Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat. 2005;90:97–104.

    Article  CAS  Google Scholar 

  2. Poplack SP, Levine GM, Henry L, Wells WA, Heinemann FS, Hanna CM, et al. A pilot study of ultrasound-guided cryoablation of invasive ductal carcinomas up to 15 mm with MRI follow-up and subsequent surgical resection. AJR. 2015;204:1100–8.

    Article  Google Scholar 

  3. •• Simmons RM, Ballman KV, Cox C, et al. A phase II trial exploring the success of cryoablation therapy in the treatment of invasive breast carcinoma: results from ACOSOG (Alliance) Z1072. Ann Surg Oncol. 2016;23:2438–45 This study was one of the first, large prospective clinical trials to explore cryoablation to be published.

    Article  Google Scholar 

  4. McArthur HL, Diab A, Page DB, et al. A pilot study of preoperative single-dose Ipilimumab and/or Cryoablation in women with early-stage breast Cancer with comprehensive immune profiling. Clin Cancer Res. 2016;22:5729–37.

    Article  CAS  Google Scholar 

  5. Dowlatshahi K, Francescatti DS, Bloom KJ. Laser therapy for small breast cancers. Am J Surg. 2002;184:359–63.

    Article  Google Scholar 

  6. Harms SE. MR-guided minimally invasive procedures. Magn Reson Imaging Clin N Am. 2001;9:381–92.

    CAS  PubMed  Google Scholar 

  7. Nori J, Gill MK, Meattini I, Delli Paoli C, Abdulcadir D, Vanzi E, et al. The evolving role of ultrasound guided percutaneous laser ablation in elderly Unresectable breast Cancer patients: a feasibility pilot study. Biomed Res Int. 2018;9141746:1–7. https://doi.org/10.1155/2018/9141746.

    Article  Google Scholar 

  8. •• Schwartzberg B, Lewin J, Abdelatif O, et al. Phase 2 open-label trial investigating percutaneous laser ablation for treatment of early-stage breast Cancer: MRI, pathology, and outcome correlations. Ann Surg Oncol. 2018;25(10):2958–64 This study is the first, large well designed, prospective clinical trials to explore laser ablation to be published.

    Article  Google Scholar 

  9. Dowlatshahi K, Francescatti D, Bloom K. Laser therapy for small breast cancers. Am J Surg. 2002;184:359–63.

    Article  Google Scholar 

  10. van Esser S, Stapper G, van Diest PJ, van den Bosch MAAJ, Klaessens JHGM, Mali WPTM, et al. Ultrasound-guided laser-induced thermal therapy for small palpable invasive breast carcinomas: a feasibility study. Ann Surg Oncol. 2009;16:2259–63.

    Article  Google Scholar 

  11. Hill CR, ter Haar GR. High intensity focused ultrasound: potential for cancer treatment. Br J Radiol. 1995;68:1296–303.

    Article  CAS  Google Scholar 

  12. Wu F, Chen WZ, Bai J, Zou JZ, Wang ZL, Zhu H, et al. Pathological changes in human malignant carcinoma treated with high-intensity focused ultrasound. Ultrasound Med Biol. 2001;27:1099–106.

    Article  CAS  Google Scholar 

  13. Furusawa H, Namba K, Thomsen S, Akiyama F, Bendet A, Tanaka C, et al. Magnetic resonance-guided focused ultrasound surgery of breast cancer: reliability and effectiveness. J Am Coll Surg. 2006;203:54–63.

    Article  Google Scholar 

  14. Gambos EC, Kacher DF, Furusawa H, Namba K. Breast focused ultrasound surgery with magnetic resonance guidance. Top Magn Reson Imaging. 2006;17:181–8.

    Article  Google Scholar 

  15. Gianfelice D, Khiat A, Amara M, Belblidia A, Boulanger Y. MR imaging-guided focused US ablation of breast cancer: histopathologic assessment of effectiveness-initial experience. Radiology. 2003;227:849–55.

    Article  Google Scholar 

  16. Furusawa H, Namba K, Nakahara H, Tanaka C, Yasuda Y, Hirabara E, et al. The evolving non-surgical ablation of breast cancer: MR guided focused ultrasound (MRgFUS). Breast Cancer. 2007;14:55–8.

    Article  Google Scholar 

  17. Furusawa H. Treatment of Breast Cancer. Plenary session presented at the second international symposium on MR-guided focused ultrasound, October 2010, Washington, DC.

  18. Napoli A, Anzidei M, Ciolina F, Marotta E, Cavallo Marincola B, Brachetti G, et al. MR-guided high-intensity focused ultrasound: current status of an emerging technology. Cardiovasc Intervent Radiol. 2013;36:1190–203.

    Article  Google Scholar 

  19. Wu F, Wang Z-B, Cao Y-D, Chen W-Z, Bai J, Zou J-Z, et al. A randomized clinical trial of high-intensity focused ultrasound ablation for the treatment of patients with localized breast cancer. Brit J Cancer. 2003;89:2227–33.

    Article  CAS  Google Scholar 

  20. Wu F, Wang Z-B, Zhu H, Chen W-Z, Zou J-Z, Bai J, et al. Extracorporeal high intensity focused ultrasound treatment for patients with breast cancer. Breast Cancer Res Treat. 2005;92:51–60.

    Article  Google Scholar 

  21. Wu F, Wang Z-B, Cao Y-D, Zhu X-Q, Zhy H, Chen W-Z, et al. Wide local ablation of localized breast cancer using high intensity focused ultrasound. J Surg Oncol. 2007;96:130–6.

    Article  Google Scholar 

  22. Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer (Breast-48), ClinicalTrials.gov Identifier: NCT03237572.

  23. • Merckel LG, Knuttel FM, Deckers R, van Dalen T, Schubert G, Peters NHGM, et al. First clinical experience with a dedicated MRI-guided high-intensity focused ultrasound system for breast cancer ablation. Eur Radiol. 2016;26:4037–46 This important study describes the use of the first breast specific focused ultrasound ablation device.

    Article  Google Scholar 

  24. Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer (Breast-48), ClinicalTrials.gov Identifier: NCT03237572.

  25. Schwartzberg, personal communication 4/18.

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of Virginia Health System, P.O. Box 800709, Charlottesville, VA, 22908-0709, USA

    David R Brenin

Authors
  1. David R Brenin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David R Brenin.

Ethics declarations

Conflict of Interest

David Brenin reports grants from Theraclion during the conduct of the study for research support.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Local-Regional Evaluation and Therapy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brenin, D.R. Ablative Treatment of Breast Cancer; Are We There Yet?. Curr Breast Cancer Rep 11, 43–50 (2019). https://doi.org/10.1007/s12609-019-0307-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-019-0307-1

Keywords

Search

Navigation